The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 320 participants.
Also called NCT03840226
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 320 participants
- Sponsor
- Registry
-
NCT03840226
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Israel
- Registry status
- Unknown status
Technical summary
Registry record NCT03840226. Randomized; single masking; primary purpose treatment. Start 2019-08-25 (actual); primary completion 2026-01-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients
- Condition
- Magnesium Deficiency
- Condition
- Heart Failure
- Intervention (Drug)
- Placebo Oral Tablet
- Intervention (Drug)
- Magnesium Oxide
- Lead sponsor
- Sheba Medical Center
- Collaborator
- Naveh Pharma (1996) Ltd.
Record details
- Record id
cardio:ct-nct03840226- Content hash
8f2c900326552b09bc8fc482d44105dee0edd4119f4a951fe7c3f946e0d41713